Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2026
Higher fibrosis-4 index is associated with 1-year in-stent restenosis after carotid artery stenting.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fujioka Tomohiro, Kanki Hideaki, Gon Yasufumi, Takasugi Junji, Kawano Tomohiro, Kitano Takaya, Murakami Shumpei, Furuya Shogo, Nakamura Hajime, Takagaki Masatoshi, Ozaki Tomohiko, Kishima Haruhiko, Sasaki Tsutomu, Mochizuki Hideki
Аннотация
BACKGROUND: In-stent restenosis (ISR) is a clinically important complication of carotid artery stenting (CAS); however, practical risk markers remain understudied. Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with atherosclerotic risk, and the Fibrosis-4 (FIB-4) index, a non-invasive marker of liver fibrosis, has been linked to carotid atherosclerosis progression. Therefore, this study examined whether the FIB-4 index was associated with ISR after CAS.
METHODS: We retrospectively analyzed 132 patients who underwent CAS between 2010 and 2023. ISR was defined as peak systolic velocity ≥175 cm/s on at least two consecutive duplex examinations. The primary analysis evaluated FIB-4 continuously per 1-SD increase using Cox models. Secondary exploratory analyses used a cohort-derived cutoff determined by the Youden index.
RESULTS: ISR occurred in 16/132 (12%) patients. When analyzed continuously, FIB-4 was not significantly associated with ISR in univariable analysis (HR per 1-SD increase, 1.34; 95% CI, 0.88-2.04; p = 0.172) or in a parsimonious model adjusted for sex and stent design (adjusted HR, 1.40; 95% CI, 0.89-2.21; p = 0.142). The cohort-derived cutoff was 2.08. In secondary exploratory analysis, FIB-4 ≥ 2.08 was associated with higher ISR risk after adjustment for sex and stent design (adjusted HR, 3.93; 95% CI, 1.42-10.9; p = 0.008).
CONCLUSIONS: Although continuous FIB-4 was not significantly associated with ISR, exploratory cutoff-based analyses suggested an association between higher FIB-4 and 1-year ISR after CAS. Further validation is required before clinical use.
METHODS: We retrospectively analyzed 132 patients who underwent CAS between 2010 and 2023. ISR was defined as peak systolic velocity ≥175 cm/s on at least two consecutive duplex examinations. The primary analysis evaluated FIB-4 continuously per 1-SD increase using Cox models. Secondary exploratory analyses used a cohort-derived cutoff determined by the Youden index.
RESULTS: ISR occurred in 16/132 (12%) patients. When analyzed continuously, FIB-4 was not significantly associated with ISR in univariable analysis (HR per 1-SD increase, 1.34; 95% CI, 0.88-2.04; p = 0.172) or in a parsimonious model adjusted for sex and stent design (adjusted HR, 1.40; 95% CI, 0.89-2.21; p = 0.142). The cohort-derived cutoff was 2.08. In secondary exploratory analysis, FIB-4 ≥ 2.08 was associated with higher ISR risk after adjustment for sex and stent design (adjusted HR, 3.93; 95% CI, 1.42-10.9; p = 0.008).
CONCLUSIONS: Although continuous FIB-4 was not significantly associated with ISR, exploratory cutoff-based analyses suggested an association between higher FIB-4 and 1-year ISR after CAS. Further validation is required before clinical use.